A low dose, continuous treatment by cyclophosphamide (100 mg/day p.o.) has been given to 141 patients with documented Müllerian ovarian cancer. From this total 134 have been evaluated for drug related toxicity. Response and survival have been studied in 72 patients in stages III, IV or in recurrence, all with at least one measurable tumor mass. Results demonstrate that this regimen of administration induces remission and prolongation of median survival with a very low level of toxicity and minimal discomfort to the patient.
ASJC Scopus subject areas